by Gordon Hensley | Jun 12, 2023 | CMS, Communications, COVID, FDA, health care, HHS |
When Covid began to run roughshod over the U.S in mid-2020 I had an opportunity to work as a “senior advisor” at the U.S. Department of Health and Human Services (HHS). I spent much of my time working with Covid “testing czar” Brett Giroir and...
by Gordon Hensley | Feb 23, 2021 | advocacy, Business, Campaign 2020, CDC, CMS, COVID, health care, HHS, Media Relations, Pharmaceutical, SNF, state government, Trump
Kudos to CBS Face the Nation moderator Margaret Brennan for her excellent interview of former Trump Administration Deputy National Security Advisor, Matthew F. Pottinger, surrounding several facets of the Trump Administration’s COVID-19 response. The discussion...
by Gordon Hensley | Oct 28, 2019 | advocacy, Business, GOP Politics, health care, Health Reform
As a Republican and admitted ideologue when it comes to assigning blame to “big government” and “regulatory overreach” for many of the nation’s ills, Axios points out today that, “Private equity firms don’t just own physician...
by Gordon Hensley | Jun 18, 2019 | advocacy, Business, CMS, health care, Medicaid funding, Pharmaceutical, state government
With pharmacy benefit managers (PBMs) under a cloud of their own making due to a business model wholly dependent upon opaque, non-transparent drug pricing practices, the Centers for Medicare and Medicaid Services (CMS) recently prohibited yet another controversial PBM...
by Gordon Hensley | Mar 26, 2019 | advocacy, Business, GOP Politics, health care, lobbying, Pharmaceutical
This more of an addenda to my last post noting how PBMs have, to their detriment, ended up on Sen. Grassley’s radar screen. Now Sen. John Cornyn (R-TX), up for reelection this cycle, has weighed in: “The whole rebate thing just looks kind of — well...
by Gordon Hensley | Feb 21, 2019 | advocacy, Business, CMS, health care, lobbying, Medicare Cuts, Pharma, U.S. House, U.S. Senate
Among the most complex but significant issues in the unfolding debate about prescription drug pricing reform is pharmacy benefit manager (PBM) rebates — or, so-called “rebates” — as many objective observers see them as kickbacks or opaque...